Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

GlobeNewswire 4 days ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

GlobeNewswire 13 days ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 12, 2024

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

GlobeNewswire July 29, 2024

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

GlobeNewswire July 16, 2024

Celldex Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 4, 2024

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

GlobeNewswire June 2, 2024

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

GlobeNewswire May 15, 2024

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 6, 2024

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

GlobeNewswire April 17, 2024

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire March 8, 2024

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

GlobeNewswire March 5, 2024

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire March 5, 2024

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

GlobeNewswire February 29, 2024

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire February 28, 2024

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

GlobeNewswire February 26, 2024

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

GlobeNewswire February 24, 2024

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire February 6, 2024

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

GlobeNewswire February 5, 2024